Program
Nitroglycerin
Also written as “Glyceryl Trinitrate”, “MED2005” and “IMX-150”.
Its studies are mostly in Raynaud Disease · Erectile Dysfunction · Coronary Artery Disease · Fissure in Ano · Connective Tissue Diseases, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediQuest Therapeutics | 40 open or running | phase 3since Dec 18, 2007 | May 29, 2007 | none ahead |
| Futura Medical Developments | 30 open or running | phase 3since Jan 15, 2019 | Jun 29, 2015 | none ahead |
| AbbVie | 20 open or running | phase 4since Aug 7, 2013 | Aug 28, 2007 | none ahead |
| Procris Pharmaceuticals | 20 open or running | phase 2since Mar 17, 2008 | Mar 17, 2008 | none ahead |
| Covis Pharma S.à.r.l. | 10 open or running | phase 2since Feb 18, 2016 | Feb 18, 2016 | none ahead |
Also a collaborator on its studies: Merck and richmond-pharmacology-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2007First study: phase 2 study in Raynaud DiseaseNew to MediQuest TherapeuticsMediQuest Therapeutics · NCT00480753 · 15 enrolled · United States
- Aug 7, 2007Phase 1 study in HealthyMediQuest Therapeutics · NCT00513994 · 6 enrolled · United States
- Aug 28, 2007AbbVie's first study: phase 3 study in Fissure in AnoNew to AbbVieAbbVie · NCT00522041 · 248 enrolled
- Dec 18, 2007Phase 3 study in Raynaud DiseaseMediQuest Therapeutics · NCT00577304 · 200 enrolled · United States
- Mar 17, 2008Procris Pharmaceuticals's first study: phase 2 study in Diabetic Peripheral NeuropathyNew to Procris PharmaceuticalsProcris Pharmaceuticals · NCT00641953 · 155 enrolled · United States
- Jun 13, 2008Phase 1 study in Raynaud DiseaseProcris Pharmaceuticals · NCT00700518 · 10 enrolled · United States
- Feb 9, 2009Phase 1 study in Raynaud DiseaseMediQuest Therapeutics · NCT00841594 · 12 enrolled · United States
- Aug 7, 2013Phase 4 study in Fissure in AnoAbbVie · NCT01920074 · United States
- Jun 29, 2015Futura Medical Developments's first study: phase 2 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT02495467 · 232 enrolled · United Kingdom
- Feb 18, 2016Covis Pharma S.à.r.l.'s first study: phase 2 study in Raynaud's Phenomenon Secondary to Connective Tissue DiseaseNew to Covis Pharma S.à.r.l.Covis Pharma S.à.r.l. · NCT02688270 · 65 enrolled · United States
- Jan 24, 2018Phase 1 study in Erectile DysfunctionFutura Medical Developments · NCT04008732 · 40 enrolled · United Kingdom
- Jan 15, 2019Phase 3 study in Erectile DysfunctionFutura Medical Developments · NCT03813992 · 1,005 enrolled · Bulgaria, Czechia, Georgia and more
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ataciguatrule | Sanofi | phase 3 | 3 |
| praliciguatrule | Ironwood Pharmaceuticals | phase 2 | 8 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03813992Erectile Dysfunction · Bulgaria, Czechia, Georgia and more | 3 | Completed | Futura Medical Developments | Jul 21, 2019 | 1,005 |
| NCT04008732Erectile Dysfunction · United Kingdom | 1 | Completed | Futura Medical Developments | Apr 16, 2018 | 40 |
| NCT02688270Raynaud's Phenomenon Secondary to Connective Tissue Disease · United States | 2 | Completed | Covis Pharma S.à.r.l. | Dec 2016 | 65 |
| NCT02495467Erectile Dysfunction · United Kingdom | 2 | Completed | Futura Medical Developments | Jul 30, 2016 | 232 |
| NCT01920074Fissure in Ano · United States | 4 | Withdrawn | AbbVie | Mar 2015 | 0 |
| NCT00841594Raynaud Disease · United States | 1 | Completed | MediQuest Therapeutics | Feb 2009 | 12 |
| NCT00700518Raynaud Disease · United States | 1 | Completed | Procris Pharmaceuticals | Nov 2008 | 10 |
| NCT00641953Diabetic Peripheral Neuropathy · United States | 2 | Completed | Procris Pharmaceuticals | Mar 2008 | 155 |
| NCT00577304Raynaud Disease · United States | 3 | UNKNOWN | MediQuest Therapeutics | Mar 2008 | 200 |
| NCT00522041Fissure in Ano | 3 | Completed | AbbVie | Jul 2008 | 248 |
| NCT00513994Healthy · United States | 1 | Completed | MediQuest Therapeutics | 6 | |
| NCT00480753Raynaud Disease · United States | 2 | Completed | MediQuest Therapeutics | 15 |
How it is read
Names in the registry
- “Nitroglycerin”, 4 entries
- “Glyceryl Trinitrate”, 4 entries
- “MED2005”, 2 entries
- “IMX-150”, 2 entries
- “Nitroglycerin spray”, 1 entry
Conditions, from the studies’ own filings
- Raynaud Disease, 4 studies
- Erectile Dysfunction, 3 studies
- Coronary Artery Disease, 2 studies
- Fissure in Ano, 2 studies
- Connective Tissue Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.